Enliven Therapeutics announced positive initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors. "We are excited about these initial Phase 1b data, the progress we made throughout 2025 and the year ahead. Our data continue to demonstrate that ELVN-001 has the potential to be the best-in-class active-site TKI for the treatment of CML and an important treatment option across all lines of therapy," said Helen Collins, M.D., Chief Medical Officer of Enliven. "Momentum has been building over the last year leading to significant interest in our Phase 3 clinical trial from sites all around the world. We are preparing for upcoming regulatory interactions with the FDA to align on dose selection and support initiation of the Phase 3 trial in the second half of 2026."
Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 40.20 USD with a low forecast of 35.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 40.20 USD with a low forecast of 35.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.160
Low
35.00
Averages
40.20
High
48.00
Current: 26.160
Low
35.00
Averages
40.20
High
48.00
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
maintain
$40 -> $48
2025-07-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$40 -> $48
AI Analysis
2025-07-02
maintain
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Enliven to $48 from $40 and keeps a Buy rating on the shares after the company presented updated results from the Phase 1a/1b ENABLE trial at EHA 2025. Following the presentation at the medical meeting, the firm contends that ELVN-001 could become "the go-to agent" in chronic myelogenous leukemia.
Goldman Sachs
Salveen Richter
NULL -> Buy
upgrade
$37
2025-06-17
Reason
Goldman Sachs
Salveen Richter
Price Target
$37
2025-06-17
upgrade
NULL -> Buy
Reason
Goldman Sachs analyst Salveen Richter assigned of Enliven with a Buy rating and $37 price target from a previous Early-Stage Biotech designation. The firm cites the company's continued positive Phase 1 data and the announcement of a planned Phase 3 initiation in 2026 for tyrosine kinase inhibitor ELVN-001 in chronic myeloid leukemia for the Buy rating. ELVN-001 remains well-tolerated, with no increased cardiovascular toxicity, and the data supports the potential for once daily dosing without the need for fasting and low drug-drug interactions, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ELVN
Unlock Now
Baird
Colleen Kusy
Outperform
maintain
$40 -> $52
2025-06-17
Reason
Baird
Colleen Kusy
Price Target
$40 -> $52
2025-06-17
maintain
Outperform
Reason
Baird analyst Colleen Kusy raised the firm's price target on Enliven to $52 from $40 and keeps an Outperform rating on the shares. The firm updated its model as its ELVN-001 data continues to show improvement which supports its compelling profile.
JonesResearch
Soumit Roy
Buy
downgrade
$36 -> $27
2025-05-16
Reason
JonesResearch
Soumit Roy
Price Target
$36 -> $27
2025-05-16
downgrade
Buy
Reason
JonesResearch analyst Soumit Roy lowered the firm's price target on Enliven to $27 from $36 and keeps a Buy rating on the shares. The company's abstract from the Phase 1 late line chronic myeloid leukemia trial with ELVN-001 "was met with a lukewarm initial stock reaction that weakened over time," the analyst tells investors in a research note. The firm says that even though ELVN-001 showed efficacy and safety profile inline with the September 2024 update with two-times the patient population, the market treated the stock with a sell on news approach. Jones sees ELVN-001 performing at least inline with Novartis' Scemblix.
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
